Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
BRD8899
AOB1381
CAS: 1404437-50-8
Chemical Name: N-[[(2S,4R)-4-[[(4-Methyl-5-isoquinolinyl)sulfonyl]amino]-2-pyrrolidinyl]methyl]-acetamide
10 Items
Quantity Discount Table - Order More To Get More Price Discount
| Quantity (mg or Unit) | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|
| 5 | $310.25 | Total: $1,551.25 |
| 10 | $262.80 | Total: $2,628.00 |
| 25 | $222.65 | Total: $5,566.25 |
| 50 | $189.80 | Total: $9,490.00 |
| 100 | $164.25 | Total: $16,425.00 |
Overview
Potent and selective inhibitor of STK33
Chemical Properties
| Molecular Formula | C17H22N4O3S |
| Molecular Weight | 362.45 |
| CAS Numbers | 1404437-50-8 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| IUPAC/Chemical Name | N-[[(2S,4R)-4-[[(4-Methyl-5-isoquinolinyl)sulfonyl]amino]-2-pyrrolidinyl]methyl]-acetamide |
| InChl Key | KAAADIFKRHNJHA-LSDHHAIUSA-N |
| InChl Code | InChI=1S/C17H22N4O3S/c1-11-7-18-8-13-4-3-5-16(17(11)13)25(23,24)21-15-6-14(20-10-15)9-19-12(2)22/h3-5,7-8,14-15,20-21H,6,9-10H2,1-2H3,(H,19,22)/t14-,15+/m0/s1 |
| SMILES Code | CC1=C2C(=CN=C1)C=CC=C2S(=O)(=O)NC3CC(NC3)CNC(=O)C |
Storage and Handling
0°C (short term), -20°C (long term), desiccated
Synonyms
BRD-8899; BRD 8899
References
1) Luo T, et al. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2860-5.